Gilead Sciences (GILD)
BMO Capital analyst Matthew Luchini assigned a Hold rating to Gilead Sciences on October 7. The company’s shares closed last Wednesday at $67.63.
According to TipRanks.com, Luchini is a 3-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $81.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD: